Omniose is developing polysaccharide conjugate vaccines against serious bacterial infections using a proprietary bioconjugation platform that enables the simultaneous production of polysaccharide antigens and engineered carrier proteins within a single _E. coli_ cell. This technology addresses the limitations of traditional chemical conjugation methods, allowing for the precise attachment of a wide range of bacterial polysaccharide antigens to improve vaccine quality and efficacy.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NIFounders
Product
Problem
Traditional chemical conjugation methods for producing polysaccharide conjugate vaccines against bacterial infections face limitations in precisely attaching a wide range of bacterial polysaccharide antigens, impacting vaccine quality and efficacy. These methods can be complex and may not be suitable for all bacterial targets.
Solution
Omniose is developing polysaccharide conjugate vaccines using a proprietary bioconjugation platform that enables the simultaneous production of polysaccharide antigens and engineered carrier proteins within a single _E. coli_ cell. This technology allows for the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins. The platform simplifies the conjugation process, potentially leading to higher quality vaccines against a broader range of bacterial targets, including Group B _Streptococcus_, _Klebsiella pneumoniae_, and _Streptococcus pneumoniae_. The company's approach expands the range of bacterial targets addressable with bioconjugate vaccines.
Target Audience
The primary target audience includes pharmaceutical companies and global health organizations focused on developing and distributing vaccines against serious bacterial infections.
Features
- Proprietary bioconjugation platform for simultaneous production of polysaccharide antigens and engineered carrier proteins.
- Precise enzymatic attachment of bacterial polysaccharide antigens within a single _E. coli_ cell.
- Capability to address a wide range of bacterial targets, overcoming limitations of traditional chemical conjugation.
- Development of vaccines against Group B _Streptococcus_, _Klebsiella pneumoniae_, and _Streptococcus pneumoniae_.
- Exclusive collaboration agreement with AstraZeneca to research potential vaccines for bacterial pathogens.